Saturday, April 6, 2013

Stocks DD Cites: Trius's Tedozolid differentiation from Pfizer's Linezolid


Read, understand and consent to the blog's DISCLAIMER here before proceeding to read the article

Presentation->Link

See slide 20, where they say 40% of Linezolid's sales (in off-label indication where long term dosing is needed)  and Linezolid safety is questionable. Tedozolid does well in safety signals in long term dosing . I think the major concern was generic linezolid in 2016 but this above data would likely put that concern to rest?




No comments:

Post a Comment